ArticleFrontiers in pharmacology2025
Knowledge, attitudes, and practices toward linezolid-serotonergic drug interactions: a cross-sectional study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Detection of clinically significant drug-drug interactions in serotonin syndrome: a multisource real-world data and pharmacovigilance study.Therapeutic advances in drug safety · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Concomitant use of linezolid with serotonergic agents may lead to serotonin syndrome, a rare but serious complication. This study assessed healthcare providers' knowledge, attitudes, and practices (KAP) to identify gaps and inform strategies to enhance patient safety. Methods: We conducted a nationwide, cross-sectional survey among physicians, pharmacists, and nurses practicing in Saudi Arabia. Participants completed a validated questionnaire designed to assess KAP related to linezolid-serotonergic drug interactions. KAP scores were categorized and analyzed using logistic regression to identify predictors associated with higher performance. Results: Among 116 respondents, 69.0% reported awareness of linezolid-serotonergic drug interaction. However, only 30.2% achieved high knowledge scores (≥6.7/10). Correct identification of serotonin syndrome, Hunter diagnostic criteria, and the recommended 2-week washout period was limited (34.5%, 34.5%, and 41.4%, respectively). Pharmacists had the highest knowledge scores (mean 5.52), followed by physicians (5.18) and nurses (2.79). In multivariable analysis, prior awareness of the interaction (AOR, 23.52; 95% CI, 2.90-190.72) and international training (AOR, 3.51; 95% CI, 1.07-11.53) were associated with higher knowledge scores. Both knowledge and attitude were significantly associated with safer practice behaviors (OR 3.04 and 8.75, respectively; p < 0.05). Conclusion: Persistent gaps in knowledge and safe prescribing practices related to the linezolid-serotonergic interaction were identified among healthcare providers in Saudi Arabia, reflecting a broader challenge globally. These findings support the need for targeted educational interventions and institution-level policies to improve awareness, enhance patient safety, and reduce preventable harm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.